Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease.

AMIA ... Annual Symposium proceedings. AMIA Symposium - 1 Jan 2015

Chen Yang, Cai Xiaoshu, Xu Rong

Abstract excerpt

Parkinson's disease (PD) is a severe neurodegenerative disorder without effective treatments. Here, we present a novel drug repositioning approach to predict new drugs for PD leveraging both disease genetics and large amounts of mouse model phenotypes. First, we identified PD-specific mouse phenotypes using well-studied human disease genes. Then we searched all FDA-approved drugs for candidates that share similar...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Discovery
Share to Drug Repositioning
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Parkinson Disease

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 26958284
PMCID: PMC4765695

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease.PMID 26958284Read ↗

Mouse model phenotypes provide information about human drug targets.Semantic proximity Read ↗

Phenome-based gene discovery provides information about Parkinson's disease drug targets.Semantic proximity Read ↗

Finding drug targeting mechanisms with genetic evidence for Parkinson’s diseaseSemantic proximity Read ↗

Repositioning drugs by targeting network modules: a Parkinson's disease case study.Semantic proximity Read ↗

Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data.Semantic proximity Read ↗

Mining drug-disease relationships as a complement to medical genetics-based drug repositioning: Where a recommendation system meets genome-wide association studies.Semantic proximity Read ↗

Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.Semantic proximity Read ↗

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disordersSemantic proximity Read ↗

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug ClassesSemantic proximity Read ↗

Repurposing the Memory-promoting Meclofenoxate Hydrochloride as a Treatment for Parkinson‘s Disease through Integrative Multi-omics analysisSemantic proximity Read ↗

Decoding Early Parkinson's: A Network-Based Approach to Drug Target IdentificationSemantic proximity Read ↗

Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.